Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NS-018 in Myelofibrosis
NCT01423851Phase 2Completed
- Sponsor
- NS Pharma, Inc.
- Start
- Jun 2011
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ilginatinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by NS Pharma, Inc.. Started Jun 2011; status: completed.
02
Drugs
ilginatinib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT01423851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01423851.